Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed grouped question UIN question first answered answering member label attachment file name title
tabling member	label

Search

1700670

registered interest
date	15/04/2024
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Ticks
house id	2
legislature	25277 pref label House of Lords
question text	To ask His Majesty's Government, following the publication of the UK Health Security Agency report Health Effects of Climate Change (HECC) in the UK: State of the evidence 2023 in January, what steps they are taking to inform health professionals of the heightened risk to public health of (1) Lyme disease, and (2) emerging tick-borne diseases, including tick-borne encephalitis, from an increase in the UK distribution of tick species as a result of a warming climate; and what advice are they providing to those exposed to this risk through work or leisure.
tabling member printed	The Earl of Caithness
uin	HL3728
answer	answer is ministerial correction date of answer 23/04/2024 answer text <p>The UK Health Security Agency (UKHSA) has an active programme to promote awareness of tick-borne diseases among local authorities, health professionals and the public by 2025 in line with the Third National Adaptation Programme. This includes Lyme disease and tick-borne encephalitis. UKHSA has worked to develop a toolkit for local authorities and key stakeholders to raise awareness of the potential risks created by ticks and tick-borne disease, a copy of which is attached. UKHSA also publishes Lyme disease data on Fingertips, which is an open access public health data platform which allows the public, health professionals, and local authorities to view trends, compare indicators and understand the incidence of Lyme disease in their area.</p><p>Clinicians are also engaged via teaching sessions for General Practitioners, seminars for infection specialists, and briefing notes to notify clinicians of the possibility of tick-borne diseases, with detail of compatible signs and symptoms. Disease messaging is shared through media, social, and stakeholder channels at a national and regional level, such as the #BeTickAware campaign which aims to raise awareness in the population, including those at risk of exposure through work or leisure.</p> answering member printed Lord Markham question first answered 23/04/2024 11:38:44 answering member 4948 label Biography information for Lord Markham attachment 1 file name Be_tick_aware_toolkit.pdf title Be_tick_aware_toolkit
tabling member	3310 label Biography information for The Earl of Caithness

1700671

registered interest
date	15/04/2024
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Drugs: Shortages
house id	2
legislature	25277 pref label House of Lords
question text	To ask His Majesty's Government what steps they are taking to mitigate the current shortage of the psychotropic medication Olanzapine, Risperidone and Haloperidol following the sudden departure of two generic manufacturers from the UK market.
tabling member printed	Lord Carlile of Berriew
uin	HL3729
answer	answer is ministerial correction date of answer 22/04/2024 answer text <p>We are aware that there have been supply constraints with olanzapine 210 milligram, 300 milligram, and 405 milligram powder and solvent for prolonged release suspension for injection. We worked with manufacturers to uplift production, and the issues were resolved in February 2024. We worked with NHS England to issue national communications containing advice on how to manage patients whilst there was a disruption to supply. We are not aware of any supply issues affecting oral presentations of olanzapine, or of any supply issues with any risperidone or haloperidol products.</p> answering member printed Lord Markham grouped question UIN HL3730 question first answered 22/04/2024 15:15:21 answering member 4948 label Biography information for Lord Markham
tabling member	1138 label Biography information for Lord Carlile of Berriew

1699944

registered interest
date	12/04/2024
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Dental Services: Standards
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, if she will introduce a system of redress for NHS dentists that fulfil less than (a) 80%, (b) 50% and (c) 10% of their performance target.
tabling member constituency	Suffolk Coastal
tabling member printed	Dr Thérèse Coffey
uin	21013
answer	answer is ministerial correction date of answer 17/04/2024 answer text <p>National Health Service dental contract holders are awarded funding at the start of each financial year, based on the contracted number of Units of Dental Activity (UDA). Contractors are required to deliver at least 96% of their contracted activity on an annual basis. Where this does not occur, the NHS reclaims the difference between the monies paid to contractors and the value of work which has been delivered. NHS England will encourage commissioners and contractors to work together to resolve underperformance against the contract at the mid-year review point, or by voluntarily rebasing their contract in the first instance. Where this is not possible, and where there have been three consecutive years of persistent underperformance, commissioners will be able to rebase contracts to the highest level of UDAs delivered over the three-year period from the following year, and recommission unused activity to other providers.</p> answering member constituency South Northamptonshire answering member printed Andrea Leadsom question first answered 17/04/2024 15:52:47 answering member 4117 label Biography information for Andrea Leadsom
tabling member	4098 label Biography information for Dr Thérèse Coffey

1699968

registered interest
date	12/04/2024
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Pharmacy: Finance
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what assessment she has made of the potential impact of medication costs on community pharmacies.
tabling member constituency	Gosport
tabling member printed	Dame Caroline Dinenage
uin	20988
answer	answer is ministerial correction date of answer 19/04/2024 answer text <p>Through the medicine margin survey, the Department assesses whether the reimbursement arrangements pay pharmacy contractors as agreed as part of the community pharmacy contractual framework (CPCF). The medicine margin survey considers what pharmacies paid for medicines by looking at their invoices compared to the amount reimbursed by the National Health Service. Where the survey finds that they have been underpaid, we increase the pharmacy contractors’ payments, and where they have been overpaid, we decrease payments.</p><p>Furthermore, where pharmacies cannot purchase products at or below the Drug Tariff NHS reimbursement price, Community Pharmacy England can request that the Department reassesses the reimbursement price. If a new reimbursement price is issued, this is known as a concessionary price.</p> answering member constituency Pendle answering member printed Andrew Stephenson grouped question UIN 20979 question first answered 19/04/2024 09:54:36 answering member 4044 label Biography information for Andrew Stephenson
tabling member	4008 label Biography information for Dame Caroline Dinenage

1699969

registered interest
date	12/04/2024
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Pharmacy: Finance
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, whether she plans to increase core community pharmacy funding.
tabling member constituency	Gosport
tabling member printed	Dame Caroline Dinenage
uin	20989
answer	answer is ministerial correction date of answer 18/04/2024 answer text <p>As part of the Community Pharmacy Contractual Framework five-year deal, we committed £2.6 billion every year to community pharmacy, and agreed not to recover £212 million in over delivered fees and margin from community pharmacies in recent years. In addition, we are now investing up to £645 million across 2023/24 and 2024/25 in Pharmacy First, for more blood pressure checks and more contraception consultations in pharmacy. We have begun the consultation with Community Pharmacy England on the national funding and contractual framework arrangements for 2024/25.</p> answering member constituency South Northamptonshire answering member printed Andrea Leadsom question first answered 18/04/2024 16:00:23 answering member 4117 label Biography information for Andrea Leadsom
tabling member	4008 label Biography information for Dame Caroline Dinenage

1699970

registered interest
date	12/04/2024
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Pharmacy: Finance
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, whether she plans to increase the scope of the Pharmacy First programme.
tabling member constituency	Gosport
tabling member printed	Dame Caroline Dinenage
uin	20990
answer	answer is ministerial correction date of answer 18/04/2024 answer text <p>Pharmacy First was launched on 31 January 2024, and as the service embeds, we will monitor and evaluate the service, and keep the conditions covered by Pharmacy First under review.</p> answering member constituency South Northamptonshire answering member printed Andrea Leadsom question first answered 18/04/2024 16:57:21 answering member 4117 label Biography information for Andrea Leadsom
tabling member	4008 label Biography information for Dame Caroline Dinenage

1699971

registered interest
date	12/04/2024
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Medical Equipment
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, whether she plans to develop a Priority Review programme for medical devices.
tabling member constituency	Gosport
tabling member printed	Dame Caroline Dinenage
uin	20991
answer	answer is ministerial correction date of answer 22/04/2024 answer text <p>The Priority Review programme is not currently planned, but the Government is taking other significant steps for medical device regulatory reform, as part of a broader Medical Technology Strategy. Further information on the Medical Technology Strategy is available at the following link:</p><p> </p><p><a href="https://www.gov.uk/government/publications/medical-technology-strategy/medical-technology-strategy" target="_blank">https://www.gov.uk/government/publications/medical-technology-strategy/medical-technology-strategy</a></p><p> </p><p>The Medicines and Healthcare products Regulatory Agency (MHRA) is responsible for regulating medical devices, and designates United Kingdom Approved Bodies to conduct conformity assessments against the relevant regulatory requirements. The MHRA works closely with Approved Bodies to ensure their timely assessment.</p><p> </p><p>Following a consultation on the future regulation of medical devices in 2021, the MHRA is leading a programme of work to introduce updated regulations for medical devices that prioritise patient safety, improve patient access to innovative medical devices, and ensure the UK remains an attractive market for medical technology innovators. In January of this year, the MHRA published a MedTech Regulatory roadmap that sets out the main activities in implementing the future regulations throughout 2024 and 2025. An international recognition framework for medical devices will form part of the future regulatory framework, which will provide an alternative route to the UK’s market, by leveraging approvals from comparable international regulators. The MHRA aims to publish an outline of the International Recognition Framework for medical devices later this spring, aligned to the Life Sciences Council, subject to necessary approvals.</p><p>In addition, the MHRA is leading the reform of the medical devices regulatory landscape and includes a new pathway to accelerate access to safe, innovative medical devices to help meet the unmet needs of patients. The Innovative Devices Access Pathway aims to bring new medical technologies and solutions to the National Health Service, to support the medical needs that are not currently being met. There are eight innovative medical technologies included in the pilot phase.</p><p>We are working alongside others to further the Life Sciences Vision, particularly improving regulation and regulatory processes around medical devices, and supporting broader ambitions in the vision aligned to the conditions set out in the Major Conditions Strategy. As we work to update the medical devices regulatory landscape, the MHRA is taking the Major Conditions Strategy into consideration, including the six groups of major health conditions.</p><p>The National Institute for Health and Care Excellence (NICE) is not a regulator but makes recommendations for the NHS on whether selected medical devices should be routinely adopted by the NHS, based on an assessment of their costs and benefits. Medical devices are prioritised for the NICE’s evaluation, in line with NICE’s published topic selection manual.</p> answering member constituency Pendle answering member printed Andrew Stephenson grouped question UIN 20992 20993 question first answered 22/04/2024 11:22:39 answering member 4044 label Biography information for Andrew Stephenson
tabling member	4008 label Biography information for Dame Caroline Dinenage

1699972

registered interest
date	12/04/2024
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Medical Equipment: Reviews
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, with reference to the Answer of 23 June 2023 to Question 189729 on Medicines and Healthcare products Regulatory Agency, whether she plans to initiate a priority review for medical devices.
tabling member constituency	Gosport
tabling member printed	Dame Caroline Dinenage
uin	20992
answer	answer is ministerial correction date of answer 22/04/2024 answer text <p>The Priority Review programme is not currently planned, but the Government is taking other significant steps for medical device regulatory reform, as part of a broader Medical Technology Strategy. Further information on the Medical Technology Strategy is available at the following link:</p><p> </p><p><a href="https://www.gov.uk/government/publications/medical-technology-strategy/medical-technology-strategy" target="_blank">https://www.gov.uk/government/publications/medical-technology-strategy/medical-technology-strategy</a></p><p> </p><p>The Medicines and Healthcare products Regulatory Agency (MHRA) is responsible for regulating medical devices, and designates United Kingdom Approved Bodies to conduct conformity assessments against the relevant regulatory requirements. The MHRA works closely with Approved Bodies to ensure their timely assessment.</p><p> </p><p>Following a consultation on the future regulation of medical devices in 2021, the MHRA is leading a programme of work to introduce updated regulations for medical devices that prioritise patient safety, improve patient access to innovative medical devices, and ensure the UK remains an attractive market for medical technology innovators. In January of this year, the MHRA published a MedTech Regulatory roadmap that sets out the main activities in implementing the future regulations throughout 2024 and 2025. An international recognition framework for medical devices will form part of the future regulatory framework, which will provide an alternative route to the UK’s market, by leveraging approvals from comparable international regulators. The MHRA aims to publish an outline of the International Recognition Framework for medical devices later this spring, aligned to the Life Sciences Council, subject to necessary approvals.</p><p>In addition, the MHRA is leading the reform of the medical devices regulatory landscape and includes a new pathway to accelerate access to safe, innovative medical devices to help meet the unmet needs of patients. The Innovative Devices Access Pathway aims to bring new medical technologies and solutions to the National Health Service, to support the medical needs that are not currently being met. There are eight innovative medical technologies included in the pilot phase.</p><p>We are working alongside others to further the Life Sciences Vision, particularly improving regulation and regulatory processes around medical devices, and supporting broader ambitions in the vision aligned to the conditions set out in the Major Conditions Strategy. As we work to update the medical devices regulatory landscape, the MHRA is taking the Major Conditions Strategy into consideration, including the six groups of major health conditions.</p><p>The National Institute for Health and Care Excellence (NICE) is not a regulator but makes recommendations for the NHS on whether selected medical devices should be routinely adopted by the NHS, based on an assessment of their costs and benefits. Medical devices are prioritised for the NICE’s evaluation, in line with NICE’s published topic selection manual.</p> answering member constituency Pendle answering member printed Andrew Stephenson grouped question UIN 20991 20993 question first answered 22/04/2024 11:22:39 answering member 4044 label Biography information for Andrew Stephenson
tabling member	4008 label Biography information for Dame Caroline Dinenage

1699973

registered interest
date	12/04/2024
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Medical Equipment
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, whether (a) the Medicines and Healthcare products Regulatory Agency and (b) NICE will prioritise the regulatory timelines for medical devices that (i) respond to conditions outlined in the Major Conditions Strategy and (ii) where there is unmet need.
tabling member constituency	Gosport
tabling member printed	Dame Caroline Dinenage
uin	20993
answer	answer is ministerial correction date of answer 22/04/2024 answer text <p>The Priority Review programme is not currently planned, but the Government is taking other significant steps for medical device regulatory reform, as part of a broader Medical Technology Strategy. Further information on the Medical Technology Strategy is available at the following link:</p><p> </p><p><a href="https://www.gov.uk/government/publications/medical-technology-strategy/medical-technology-strategy" target="_blank">https://www.gov.uk/government/publications/medical-technology-strategy/medical-technology-strategy</a></p><p> </p><p>The Medicines and Healthcare products Regulatory Agency (MHRA) is responsible for regulating medical devices, and designates United Kingdom Approved Bodies to conduct conformity assessments against the relevant regulatory requirements. The MHRA works closely with Approved Bodies to ensure their timely assessment.</p><p> </p><p>Following a consultation on the future regulation of medical devices in 2021, the MHRA is leading a programme of work to introduce updated regulations for medical devices that prioritise patient safety, improve patient access to innovative medical devices, and ensure the UK remains an attractive market for medical technology innovators. In January of this year, the MHRA published a MedTech Regulatory roadmap that sets out the main activities in implementing the future regulations throughout 2024 and 2025. An international recognition framework for medical devices will form part of the future regulatory framework, which will provide an alternative route to the UK’s market, by leveraging approvals from comparable international regulators. The MHRA aims to publish an outline of the International Recognition Framework for medical devices later this spring, aligned to the Life Sciences Council, subject to necessary approvals.</p><p>In addition, the MHRA is leading the reform of the medical devices regulatory landscape and includes a new pathway to accelerate access to safe, innovative medical devices to help meet the unmet needs of patients. The Innovative Devices Access Pathway aims to bring new medical technologies and solutions to the National Health Service, to support the medical needs that are not currently being met. There are eight innovative medical technologies included in the pilot phase.</p><p>We are working alongside others to further the Life Sciences Vision, particularly improving regulation and regulatory processes around medical devices, and supporting broader ambitions in the vision aligned to the conditions set out in the Major Conditions Strategy. As we work to update the medical devices regulatory landscape, the MHRA is taking the Major Conditions Strategy into consideration, including the six groups of major health conditions.</p><p>The National Institute for Health and Care Excellence (NICE) is not a regulator but makes recommendations for the NHS on whether selected medical devices should be routinely adopted by the NHS, based on an assessment of their costs and benefits. Medical devices are prioritised for the NICE’s evaluation, in line with NICE’s published topic selection manual.</p> answering member constituency Pendle answering member printed Andrew Stephenson grouped question UIN 20991 20992 question first answered 22/04/2024 11:22:40 answering member 4044 label Biography information for Andrew Stephenson
tabling member	4008 label Biography information for Dame Caroline Dinenage

1699978

registered interest
date	12/04/2024
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Diabetes: Health Services
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what assessment she has made of the potential impact of discontinuing funding for T1DE pilot schemes on the health and well-being of patients living with type 1 diabetes with disordered eating.
tabling member constituency	Knowsley
tabling member printed	Sir George Howarth
uin	20895
answer	answer is ministerial correction date of answer 18/04/2024 answer text <p>NHS England has provided funding for eight integrated care boards (ICBs) across the country to support the development and establishment of Type 1 Diabetes with Disordered Eating (T1DE) services in every National Health Service region. Funding has been provided on a pump prime basis, and the responsibility for the longer-term sustainable provision of care for these patients sits with the relevant integrated care system.</p><p>A nationally commissioned evaluation has shown the positive impact that the provision of T1DE services can have for patients, including reductions in HbA1c, which is linked to reduced rates of diabetes complications, and reduced rates of emergency admissions.</p><p>It’s the role of the ICBs to consider the health needs of their populations, in making decisions about the care that is provided. It is expected that ICB leads consider these evaluation findings alongside the risk to patient health and wellbeing of the discontinuation of service provision, as well as other local contextual factors in making decisions about the future provision of T1DE services.</p> answering member constituency Pendle answering member printed Andrew Stephenson question first answered 18/04/2024 12:53:21 answering member 4044 label Biography information for Andrew Stephenson
tabling member	481 label Biography information for Sir George Howarth